Abstract:Abstract High-grade serous ovarian carcinoma (HGSOC) is typically diagnosed at an advanced stage (III or IV) when the cancer is no longer locally confined and average 5-year survival rates are below 30%. Despite frequently having favorable initial responses to therapy, approximately 80% of HGSOC patients experience tumor recurrence and develop chemoresistance. This highlights the urgent need to better understand the mechanisms that drive transformation and tumor cell survival in early and late stages of this disease. Altered expression of BCL-2 family proteins that control the intrinsic apoptosis pathway is a prominent mechanism by which pre-cancerous cells evade cell death and tumor cells develop therapy resistance. Therefore, we sought to elucidate how changes in apoptotic regulation may contribute to neoplastic transformation and chemoresistance in HGSOC in order to uncover potential opportunities for improving early detection and treatment strategies. Because HGSOC is thought to develop predominately from fallopian tube secretory epithelial cells (FTSECs), we used immortalized and tumorigenic FTSEC lines in addition to well-validated HGSOC cell lines to measure apoptotic sensitivity and survival dependencies at three stages of transformation. Based on BH3 profiling and flow cytometry-based cell death analysis, we found that FTSECs and HGSOC cells are highly dependent on the BCL-2 family pro-survival protein BCL-XL to resist initiation of apoptosis. This rendered them particularly sensitive to BCL-XL inhibitors, including the first-generation BH3 mimetic A1331852 as well as novel proteolysis-targeting chimeras (PROTACs) that degrade BCL-XL. We also found that transformation by activation of the c-Myc oncogene increases apoptotic sensitivity and chemosensitivity of FTSECs while activation of Ras has the opposite effect and contributes to chemoresistance. Transcriptional profiling of primary tissue revealed that expression levels of pro-apoptotic BAX and BAK, which initiate apoptosis by causing mitochondrial outer membrane permeabilization, increase during ovarian tumorigenesis, as do levels of BCL-XL. Further, to gain insight into mechanisms that may alter apoptosis during tumorigenesis, we are investigating how ovulation-related exposures drive apoptotic dysregulation in the formation of HGSOC precursor lesions, as greater number of lifetime ovulatory cycles is a major risk factor associated with this disease. We are exposing 2D and 3D models of the fallopian tube epithelium to patient-derived follicular fluid, known to contain mutagenic and inflammatory mediators, as well as sex steroid hormones which are enriched in follicular fluid and have been shown to control expression of BCL-2 family proteins. Again, using BH3 profiling, flow cytometry-based cell death analysis, and gene and protein expression measurements, we will uncover how acute and chronic exposures alter the expression, function and interaction of BCL-2 family proteins and may predispose the putative cell of origin of HGSOC to neoplastic transformation. Citation Format: Lissah K. Johnson, Maryam Azimi, Xingping Qin, Cameron Fraser, Elizabeth Stover, Yang Yang, Daohong Zhou, Bo Rueda, Kristopher Sarosiek. Uncovering novel vulnerabilities in ovarian cancer by studying cell death in neoplastic transformation [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B109.

The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20

Combined inhibition of JAK1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells

Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Abstract B058: Targeting mediator kinase CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma

Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential

Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma

Abstract 3827: Histone Methytransferase SMYD3 Promotes Invasion in Ovarian Carcinoma Spheroids

Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

Complex IIa Formation and ABC Transporters Determine Sensitivity of OSCC to Smac Mimetics

Abstract B109: Uncovering novel vulnerabilities in ovarian cancer by studying cell death in neoplastic transformation

In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation

SMAC mimetics overcome apoptotic resistance in ovarian cancer through MSLN-TNF alpha axis

MYC and HSF1 Cooperate to Drive PLK1 inhibitor Sensitivity in High Grade Serous Ovarian Cancer

Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis

Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin

Abstract 3237: KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer

CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer